FIFTH BUSINESS FINANCING MODIFICATION AGREEMENTBusiness Financing Modification Agreement • November 9th, 2017 • ChromaDex Corp. • Medicinal chemicals & botanical products
This Fifth Business Financing Modification Agreement (this “Agreement”) is entered into as of August 21, 2017, by and among CHROMADEX CORPORATION, a Delaware corporation, CHROMADEX, INC., a California corporation, CHROMADEX ANALYTICS, INC., a Nevada corporation, HEALTHSPAN RESEARCH LLC, a Delaware limited liability company (each, a “Borrower” and collectively, “Borrowers”), and WESTERN ALLIANCE BANK, an Arizona corporation (“Lender”).
ASSET PURCHASE AGREEMENT BY AND AMONG COVANCE LABORATORIES INC., CHROMADEX, INC., CHROMADEX ANALYTICS, INC., AND CHROMADEX CORPORATION DATED August 21, 2017Asset Purchase Agreement • November 9th, 2017 • ChromaDex Corp. • Medicinal chemicals & botanical products • Delaware
AMENDMENT TO ASSET PURCHASE AGREEMENTAsset Purchase Agreement • November 9th, 2017 • ChromaDex Corp. • Medicinal chemicals & botanical products • Delaware
THIS AMENDMENT TO ASSET PURCHASE AGREEMENT (this “Amendment”) is made and entered into as of September 5, 2017, by and among (i) COVANCE LABORATORIES INC., a Delaware corporation (“Purchaser”); (ii) CHROMADEX, INC., a California corporation (“ChromaDex”); (iii) CHROMADEX ANALYTICS, INC., a Nevada corporation and wholly-owned subsidiary of ChromaDex (“ChromaDex Analytics”); and (iv) CHROMADEX CORPORATION, a Delaware corporation and the sole shareholder of ChromaDex and the ultimate parent company of ChromaDex Analytics (the “Shareholder”).
